UroGen Pharma Ltd. URGN
30.36 USD -4.04 (-11.74%)
Nov 4, 2026, 11:42 AM EST
27.55 Day range 34.17
16.50 52-week range 50.81
- YTD
- +29.63%
- 1 year
- +53.26%
News
benzinga.com UroGen Pharma Q3 EPS $(0.03) Misses $0.14 Estimate, Sales $89.001M Miss $89.918M Estimate UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.14 by 121.43 percent. This is a 95.65 percent increase over losses of…
globenewswire.com UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel…
globenewswire.com UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
globenewswire.com UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell…
benzinga.com UroGen Pharma Shares Results From 5-Year Follow-Up Study On Olympus Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended…
globenewswire.com UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO Results demonstrate sustained disease control through…
benzinga.com HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $75 price target.
benzinga.com UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platformAgreement also includes an…
benzinga.com UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a…- benzinga.com Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58 Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.
benzinga.com HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75 HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.- benzinga.com TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60 TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.
- benzinga.com UroGen Pharma Q2 EPS $(0.28) Beats $(0.29) Estimate, Sales $72.456M Beat $63.526M Estimate UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 73.33 percent increase over losses of…
- benzinga.com Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42 Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.
- benzinga.com Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50 Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.
- benzinga.com UroGen Receives USPTO Notice Of Allowance For Patent Covering Treatment Of Recurrent LG-IR-NMIBC With Thermally Gelling Mitomycin; Claims Supported By ENVISION And ATLAS Trials, Patent To Expire July 2044 UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received…
- benzinga.com UroGen Pharma Receives FDA IND Application Clearance For Its Investigational Oncolytic Virus UGN-501 The IND clearance enables initiation of a planned Phase 1 clinical study in patients with non-muscle invasive bladder cancer (NMIBC). The Phase 1 study is expected to begin in Q4 2026 and will…
benzinga.com HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $45 price target.- benzinga.com UroGen Pharma Announces Settlement And License Agreement With Teva Pharmaceuticals Relating to JELMYTO This Agreement resolves the patent litigation UroGen initiated in response to Teva's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration ("FDA") seeking…
benzinga.com HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $45 price target.- benzinga.com UroGen Announces That UGN-103 Achieved A 94.5% Durability Of Response At Six Months In The Ongoing Phase 3 UTOPIA Trial For Intravesical Solution In Patients With Bladder Cancer The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION trial.…
benzinga.com UroGen Pharma Announces 36-Month Duration Of Response By Kaplan-Meier Estimate In Patients Who Achieved Complete Response At Three Months In Pivotal Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution. 64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only FDA-Approved Medicine for Recurrent Low-Grade…- benzinga.com HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $45 HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $40 to $45.
- benzinga.com Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40 Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and raises the price target from $34 to $40.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com UroGen Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - benzinga.com UroGen Pharma Q1 EPS $(0.47) Beats $(0.48) Estimate, Sales $50.959M Beat $44.820M Estimate UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 48.91 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 2, 2026
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday 
benzinga.com US Stocks Likely To Rebound After Sharp Decline Amid Israel-Iran Conflict: S&P 500 Historically Moves Higher After Wars, Says Expert U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket.
benzinga.com Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - benzinga.com Earnings Scheduled For May 12, 2025
benzinga.com Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday 
benzinga.com This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Earnings Scheduled For March 10, 2025
benzinga.com Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket 
benzinga.com PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.- benzinga.com Earnings Scheduled For March 14, 2024 Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 14, 2023 Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Earnings Scheduled For March 16, 2023 Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.
- benzinga.com Earnings Scheduled For November 10, 2022 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.
- benzinga.com Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
- benzinga.com Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.